Shares in Genmab rose by as much as 9% on the morning of 4 February after it announced a nearly 30% overall response rate in a Phase II trial of its anti-CD38 antibody product daratumumab as a monotherapy in double refractory multiple myeloma patients. The product already has a breakthrough therapy designation for this indication.
Genmab rises on Phase II daratumumab promise in double refractory myeloma
Shares in Genmab rose by as much as 9% on the morning of 4 February after it announced a nearly 30% overall response rate in a Phase II trial of its anti-CD38 antibody product daratumumab as a monotherapy in double refractory multiple myeloma patients. The product already has a breakthrough therapy designation for this indication.
More from Anticancer
• By
BeiGene’s Phase III ociperlimab joins the list of failed TIGIT inhibitors, as candidates from Roche, Merck & Co. and others have failed late-stage studies.
• By
Investing heavily in antibody-drug conjugates, AbbVie is pioneering a dual STEAP1xPSMA-targeting approach in prostate cancer, as other candidates advance.
• By
Strong sales growth for the German group’s SGLT2 inhibitor in 2024
• By
A Phase III trial testing the cortisol modulator showed a benefit on PFS and OS in patients with platinum-resistant ovarian cancer.
More from Therapy Areas
• By
Strong sales growth for the German group’s SGLT2 inhibitor in 2024
• By
The study’s failure in the overall MDD population was not a surprise, but solriamfetol’s efficacy in MDD with EDS provided a rationale for testing it in that subpopulation.
• By
After failing a Phase II monotherapy study in early Parkinson’s, Cerevance will focus on adjunctive therapy without abandoning the monotherapy concept.